2023
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Gandhi R, Bedimo R, Hoy J, Landovitz R, Smith D, Eaton E, Lehmann C, Springer S, Sax P, Thompson M, Benson C, Buchbinder S, del Rio C, Eron J, Günthard H, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA 2023, 329: 63-84. PMID: 36454551, DOI: 10.1001/jama.2022.22246.Peer-Reviewed Original ResearchConceptsPrevention of HIVAntiretroviral therapySubstance use disordersAntiretroviral drugsUse disordersCertain antiretroviral medicationsDaily oral regimenInhibitor-containing regimensManagement of comorbiditiesMonkeypox virus infectionDiagnosis of HIVSARS-CoV-2 pandemicCare of peopleGlobal health emergencyInitial therapyOral regimenAdherence supportMetabolic complicationsPreexposure prophylaxisViral suppressionAntiretroviral medicationsOral medicationsHIV infectionLaboratory monitoringInjectable therapies
2022
Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice 2022, 17: 6. PMID: 35101115, PMCID: PMC8802273, DOI: 10.1186/s13722-022-00286-6.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineCOVID-19HumansNarcotic AntagonistsOpioid-Related DisordersSARS-CoV-2VeteransConceptsOpioid use disorderVeterans Healthcare AdministrationFormulations of buprenorphineComparative effectiveness trialOpioid useEffectiveness trialUse disordersOpioid epidemicSublingual buprenorphine/naloxoneSevere opioid use disorderBuprenorphine/naloxoneUS opioid epidemicClinical effectiveness trialStandard of careEffective medication treatmentsExtended-release formulationUrgent clinical needLong-term trialsHepatitis BSecondary outcomesSevere sequelaeOpioid abstinencePrimary outcomeMedication treatmentTRIAL REGISTRATION